Target Name: MIR219B
NCBI ID: G100616335
Review Report on MIR219B Target / Biomarker Content of Review Report on MIR219B Target / Biomarker
MIR219B
Other Name(s): hsa-mir-219b | hsa-miR-219b-5p | mir-219b | MIR2964A | hsa-miR-219b-3p | microRNA 219b | MicroRNA 219b

MIR219B: A Potential Drug Target and Biomarker

Mir219B, a protein expressed in human tissues, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for drug developers. In this article, we will explore the potential of MIR219B as a drug target and biomarker.

The MIR219B Protein

MIR219B is a protein that is expressed in various human tissues, including muscle, nerve, and heart cells. It is a member of the MIR family of scaffold proteins, which are known for their ability to interact with various signaling molecules, including TGF-β1, Wnt, and Notch. MIR219B is characterized by a unique N-terminal region that contains a farnesylated cysteine residue, which is known to be a key structural determinant for protein stability and stability-dependent signaling.

MIR219B functions as a negative regulator of the TGF-β1 signaling pathway. TGF-β1 is a cytokine that plays a crucial role in cell growth, differentiation, and repair. It is a potent stimulator of cell proliferation and has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MIR219B functions as a negative regulator of TGF-β1 by preventing its accumulation in the cell, which is thought to limit its signaling effects.

MIR219B has also been shown to play a role in the regulation of the Wnt signaling pathway, which is involved in cell-cell adhesion and the development of various tissues. MIR219B has been shown to regulate the activity of the Wnt receptor, which is critical for the development and maintenance of tissues, including neural networks and blood vessels.

MIR219B as a Potential Drug Target

MIR219B's unique structure and function make it an attractive target for drug developers. Its ability to regulate TGF-β1 and Wnt signaling pathways suggests that it may be a useful target for diseases that are characterized by abnormal signaling pathways. MIR219B has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the challenges in targeting MIR219B as a drug target is its expression and stability in human tissues. MIR219B is expressed in various human tissues, including muscle, nerve, and heart cells, and its stability is affected by various factors, including the expression level, localization, and processing. Understanding the mechanisms that regulate MIR219B stability and expression may be critical for the development of effective therapies.

MIR219B as a Biomarker

MIR219B may also be used as a biomarker for various diseases. Its unique structure and function make it an attractive target for diagnostic tests. For example, MIR219B has been shown to be expressed in various cancer types, including breast, lung, and ovarian cancer. Its expression may be used as a diagnostic biomarker for these diseases.

In addition to its potential as a drug target, MIR219B is also a potential biomarker for various diseases. Its expression has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, MIR219B has been shown to be involved in the development and progression of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

MIR219B has also been shown to be involved in various physiological processes, including cell growth, migration, and invasion. Its expression may be used as a biomarker for

Protein Name: MicroRNA 219b

The "MIR219B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR219B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145